When classified as HER2-negative and treated with palliative chemotherapy [1], even if HER2-0 has more adverse tumor characteristics than HER2-low, clinical trials also show no difference in survival outcomes between the two [11,14,15,16], raising the question of whether HER2-low BC is overtreated or undertreated? This evidence concerns the gene ERBB2 and breast cancer.